The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions

Fragoulis, G. E., Brock, J., Basu, N. , McInnes, I. B. and Siebert, S. (2021) The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. Journal of Allergy and Clinical Immunology, 148(4), pp. 941-952. (doi: 10.1016/j.jaci.2021.08.010) (PMID:34450118)

Full text not currently available from Enlighten.

Abstract

JAK inhibitors (JAKIs) are a new class of targeted therapy that have entered clinical practice for the treatment of immune-mediated rheumatic conditions. JAKIs can block the signaling activity of a variety of proinflammatory cytokines and therefore have the potential to mediate therapeutic benefits across a wide range of immune-mediated conditions. Several JAKIs are licensed, and many more are undergoing clinical trials. Here we provide a narrative review of the current and upcoming JAKIs for adult immune-mediated rheumatic and related conditions, with a specific focus on efficacy in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, psoriasis, and inflammatory bowel disease. The overall safety profile of JAKIs appears largely comparable to that of existing biologic cytokine-targeting agents, particularly, TNF inhibitors, apart from risk of herpes zoster, which is increased for JAKIs. Importantly however, unresolved safety concerns remain, particularly relating to increased venous thromboembolism.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain and Basu, Professor Neil and Fragkoulis, Dr Georgios and Siebert, Professor Stefan and Brock, Dr James
Authors: Fragoulis, G. E., Brock, J., Basu, N., McInnes, I. B., and Siebert, S.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Research Centre:College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Immunobiology
Journal Name:Journal of Allergy and Clinical Immunology
Publisher:Elsevier
ISSN:0091-6749
ISSN (Online):1097-6825
Published Online:24 August 2021

University Staff: Request a correction | Enlighten Editors: Update this record